top of page
AAO 2025: ANTERIOR SEGMENT SHOWCASE
Moderators: Kuldev Singh, MD, MPH, Program Co-Chair and Julie M. Schallhorn, MD, MS, Program Committee
Panel: Damien Gatinel, MD, PhD, Head, Anterior Segment and Refractive Surgery, Rothschild Foundation Hospital, Sarah H. Van Tassel, MD, Associate Professor of Ophthalmology, Director, Glaucoma Service, Weill Cornell Medicine, and Ryan Zimmerman, MHA, Managing Director, Equity Research–Medical Technology, BTIG
Room: W221
Start | Company | Presenter |
|---|---|---|
1:30 PM | Introduction | Robert L. Avery, MD |
1:31 PM | AAVantgarde | Natalia Misciattelli, PhD, CEO |
1:36 PM | Adverum Biotechnologies, Inc., a wholly owned subsidiary of Eli Lilly and Company | Star Seyedkazemi, PharmD, Chief Development Officer |
1:41 PM | Discussion | |
1:44 PM | Coave Therapeutics | Rodolphe Clerval, CEO |
1:49 PM | Restore Vision, Inc | Elizabeth K. Messersmith, PhD, Consultant, Clinical Dev and R&D Strategy |
1:57 PM | Discussion | |
2:00 PM | Luxa Biotechnology | Keith Dionne, PhD, CEO |
2:05 PM | Astellas Pharma | Ha Tran, MD, MS, Medical Head, BioPharma and Ophthalmology Development |
2:10 PM | Discussion | |
2:13 PM | EyePoint, Inc | Ramiro Ribeiro MD, PhD, Chief Medical Officer |
2:18 PM | Ocular Therapeutix, Inc | Peter Kaiser MD, Chief Development Officer |
2:23 PM | Asvattha Therapeutics, Inc | Susan Schneider, MD, Acting Chief Medical Officer |
2:28 PM | Discussion | |
2:32 PM | Neurotech Pharmaceuticals, Inc | Rich Small, CEO |
2:37 PM | Re-Vana Therapeutics | Hans Christinger, Chief Business Officer |
2:42 PM | Discussion | |
2:45 PM | Optigo Biotherapeutics | Ali Ardakani, CEO |
2:50 PM | Valitor | Wesley M. Jackson, PhD, VP, Business Development |
2:55 PM | Discussion | |
2:58 PM | Conclusion | LejlaVajzovic, MD |
3:00 PM | End of Session |
Anchor 1
bottom of page